April 7, 2026 Rapid Novor Inc., developer of the EasyM® blood-based minimal residual disease (MRD) test for multiple myeloma, today announced the completion of patient enrollment in its Canadian prospective clinical study. The study is evaluating the clinical utility of EasyM® for MRD monitoring in patients with newly diagnosed multiple myeloma (NDMM). A [...]
March 10, 2026 Rapid Novor Inc., a Canadian biotechnology leader, announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, enabling the company to begin testing patients in Canada. This milestone represents the first time highly sensitive measurable residual disease (MRD) monitoring [...]
July 19, 2024 Read the latest article from HealthTree Foundation covering EasyM™, our novel, ultra sensitive blood-based clonotypic peptides mass spectrometry assay for the monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM). In this article, learn about how MRD is monitored with current and up-and-coming technologies. Discover the benefits of [...]
May 14, 2024 A Canadian Multiple Myeloma (MM) clinical trial sponsored by Rapid Novor, has enrolled its first patient in partnership with Princess Margaret Cancer Center (PMCC) in Toronto. This is the first Canadian prospective clinical study aiming to evaluate the EasyM™ assay (mass spectrometry measurement of a myeloma biomarker) for disease response in [...]
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma Dr. Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, presents the latest poster on EasyM, a novel clonotypic peptides mass spectrometry blood test for MRD monitoring, at the annual ASH 2023 conference. In this study, EasyM mass [...]
March 16, 2023 Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its diagnostic laboratory obtained the Clinical Laboratory Improvement Amendments (CLIA) certification for their EasyM™ assay as a Laboratory Developed Test (LDT). EasyM™ is the world’s first personalized blood test for Multiple Myeloma to receive such [...]
Clonotypic mass spectrometry with EasyM assay for MRD detection in multiple myeloma Dr. Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, comments on the feasibility of clonotypic peptides mass spectrometry with EasyM assay for measurable residual disease (MRD) detection in the peripheral blood (PB) of patients with multiple myeloma. VIEW [...]